The Journal of Urology
Volume 177, Issue 4 , Pages 1307-1312 , April 2007

Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study

  • Julie N. Graff

      Affiliations

    • Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon
    • Oregon Health and Science University Cancer Institute, Portland, Oregon
    • ,
  • Motomi Mori

      Affiliations

    • Biostatistics Shared Resource, Portland, Oregon
    • ,
  • Hong Li

      Affiliations

    • Biostatistics Shared Resource, Portland, Oregon
    • ,
  • Mark Garzotto

      Affiliations

    • Division of Urology, Oregon Health and Science University, Portland, Oregon
    • Urology Section, Portland Veterans Affairs Medical Center, Portland, Oregon
    • ,
  • David Penson

      Affiliations

    • Departments of Urology and Preventive Medicine, University of Southern California/Norris Cancer Center, Los Angeles, California
    • Financial interest and/or other relationship with Dendreon, Sanofi-Aventis, Pfizer and Boehringer-Ingelheim.
    • ,
  • Arnold L. Potosky

      Affiliations

    • Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
    • ,
  • Tomasz M. Beer

      Affiliations

    • Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon
    • Oregon Health and Science University Cancer Institute, Portland, Oregon
    • Corresponding Author InformationCorrespondence: Department of Medicine, Oregon Health and Science University, Mail Code CR-145, 3181 Southwest Sam Jackson Park Rd., Portland, Oregon 97239 (telephone: 503-494-0365; FAX: 503-494-6197).

Received 24 August 2006

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106
  2. Scardino P. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005;3(suppl.):S29
  3. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:1864
  4. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52:154
  5. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295
  6. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937
  7. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781
  8. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561
  9. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615
  10. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981
  11. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708
  12. Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int. 2005;96:503
  13. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91:1719
  14. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  15. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977
  16. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191
  17. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid?. J Natl Cancer Inst. 2001;93:1822
  18. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94:430
  19. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  20. Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163:1743

 Supported by Public Health Service Contracts N01PC67000, N01PC67005, N01PC67006, N01PC67007, N01PC67009 and N01PC67010 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

PII: S0022-5347(06)03125-9

doi: 10.1016/j.juro.2006.11.054

The Journal of Urology
Volume 177, Issue 4 , Pages 1307-1312 , April 2007

Article Tools

* Image Usage & Resolution